COMMUNIQUÉS West-GlobeNewswire

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

31/10/2024 - 03:29

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“ [...]

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

31/10/2024 - 02:00

ICoN-1 study presentation planned November 1 at NTM Symposium Australia Study is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn [...]

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

31/10/2024 - 00:30

-New testing method highlights link between protofibrils and biomarkers for neurodegeneration- -Patient and caregiver perspectives on five-year treatment with lecanemab - - Utilization of blood biomarkers to predict [...]

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

31/10/2024 - 00:11

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the [...]

Greenhouse Treatment Center Joins Elite Group of Veteran Ready Addiction Treatment Providers with New PsychArmor Certification

30/10/2024 - 23:21

GRAND PRAIRIE, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Greenhouse Treatment Center recently achieved Veteran Ready Certification from PsychArmor, a nonprofit organization dedicated to military culture training. This [...]

Guardion Health Sciences Announces Filing of Certificate of Dissolution

30/10/2024 - 22:37

HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Secretary of State of [...]

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

30/10/2024 - 22:00

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, [...]

23andMe Regains Compliance With Nasdaq Listing Requirements

30/10/2024 - 22:00

SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the Company has regained [...]

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

30/10/2024 - 21:45

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for [...]

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

30/10/2024 - 21:41

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug [...]

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

30/10/2024 - 21:30

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]

Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024

30/10/2024 - 21:30

NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]

STERIS Declares Dividend of $0.57 per share

30/10/2024 - 21:30

DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is [...]

VitalHub Announces Acquisition of Strata Health

30/10/2024 - 21:30

TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Strata Health Solutions Inc. (“Strata [...]

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

30/10/2024 - 21:30

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold [...]

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

30/10/2024 - 21:20

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday [...]

Prenetics Announces Participation in the Sidoti Virtual Micro Cap Investor Conference

30/10/2024 - 21:15

CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on [...]

TOMI Environmental Solutions, Inc. Reports Consecutive Quarterly Net Profit

30/10/2024 - 21:15

- Company Reports Operating Income of $149,000 and Positive Net Income - Performance Driven by Growth in International, Mobile Equipment, and iHP Corporate Service Sales FREDERICK, Md., Oct. 30, 2024 (GLOBE NEWSWIRE [...]

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

30/10/2024 - 21:15

First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with either irinotecan or [...]